Aflibercept

Therapeutic indications

Aflibercept is indicated for:

Visual impairment due to diabetic macular oedema (DME)

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravitreal - 2 mg once every month

Neovascular (wet) age-related macular degeneration (AMD)

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravitreal - 2 mg once every month

Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravitreal - 2 mg once every month

Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravitreal - 2 mg once every month

Metastatic colorectal cancer (MCRC)

Irrespective of gender only Adults (18 years old or older)

Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 4 mg/kg once every 2 weeks

Contraindications

Active ingredient Aflibercept is contraindicated in the following cases:

Ocular, periocular, intraocular inflammation or infection

Active or suspected ocular or periocular infection.

Active severe intraocular inflammation.

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

Summary of product characteristics (SPC) 2018: EYLEA Solution for injection
Summary of product characteristics (SPC) 2017: ZALTRAP Concentrate for solution for infusion

Previous: Overview
Next: Precautions